Immunotherapeutic Strategies For The Treatment Of Glioma

Immunotherapeutic Strategies for the Treatment of Glioma provides a review of the current state of immunotherapy for primary brain tumors. The topic is of interest to patients, clinicians, and researchers alike, particularly given the recent failure of large clinical trials. This book serves as an overview of the most promising approaches in the field and provides a foundation for considering novel and combination therapies moving forward. The book discusses several types of immunotherapies for glioma, such as peptide, dendritic cell and heat shock protein vaccines; immune checkpoint blockade; myeloid cells as target; oncolytic viruses; and CAR T cell therapy. Additionally, it discusses the mechanisms of immune suppression in patients and immunogenomics. This volume is a valuable source for cancer researchers, oncologists and several members of biomedical field who are interested in novel strategies to fight glioblastoma. Summarizes the work in immunotherapy for glioma to-date, including the available evidence from preclinical studies and clinical trials Reviews the challenges and successes of the most promising strategies for brain tumor immunotherapy Provides a foundation for considering novel and combination therapies moving forward

This book is a compilation of articles that brings together current knowledge from an international team of contributors who are dedicated investigators exploring novel strategies for the treatment of glioblastoma. These articles describe some of the latest concepts that will provide students, researchers and clinicians with an overview of the therapeutic approaches being developed in the field of neuro-oncology to combat this deadly disease.

Treatment of glioma is currently one of the most challenging problems in oncology, as well as in neurosurgery. Despite major advances in our understanding of the pathomechanism, diagnosis by imaging and the availability of powerful therapeutic tools, the life expectancy of patients with glioblastoma has only been slightly prolonged and a cure remains elusive. None of the currently available surgical tools, including operative microscopes, lasers and image-guided surgery, can enable the detection and removal of all of the tumor tissue. In recent years, however, the landscape has been changing immeasurably, and molecular studies over the past two decades have identified a variety of genetic aberrations that are specifically associated with individual types of gliomas. In addition, certain molecular abnormalities have been linked to therapy responses, thereby establishing clinical biomarkers and molecular targets, and the use of novel agents is being investigated. These agents have been specifically engineered to exert specific cytotoxicity against gliomas, either on their own as single agents or in combination with other modalities. Moreover, there has been an enormous surge of interest in the area of immunology and immunotherapy, which has been facilitated by our understanding of the molecular basis of gliomas. Although several kinds of immunotherapeutic trials have been undertaken, we still await a great breakthrough in terms of clinical efficacy to prolong the survival time of glioma patients.

An authoritative panel of researchers and clinicians critically reviews the entire field to provide a comprehensive guide to modern brain tumor immunotherapy and thereby enhance future research in this area. The contributors detail many of the key laboratory experiments and clinical protocols that are currently being investigated, integrate the available information from previous and ongoing research, and help define the current status of the field. Topics range from adoptive cellular and antibody-mediated immunotherapy of brain tumors to tumor vaccines and related strategies, and include many vanguard experimental strategies and immunological techniques for studying brain tumor immunotherapy. Cutting-edge and comprehensive, Brain Tumor Immunotherapy brings together all the important recent advances in our understanding of central nervous system tumor immunology and illustrates in powerful detail the many new applications now harnessing the immune response for brain tumor therapeutics.

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts on the science and clinical management of glioblastoma chemoresistance. The book discusses topics such as molecular mechanisms of chemoresistance, experimental models to study chemoresistance, chemoresistance to drugs other than Temozolomide, and specific strategies to reverse chemoresistance. Additionally, it encompasses information on how to mitigate chemoresistance by targeted enhancement of p53 function. This book is a valuable resource for cancer researchers, oncologists, neuro-oncologists and other members of the biomedical field. Glioblastoma (GBM) is the most invasive and malignant primary brain tumor in humans with poor survival after diagnosis, therefore it is imperative that molecular and cellular mechanisms behind therapy resistant GBM cells, as well as the therapeutic strategies available to counter the resistance are comprehensively understood. Provides comprehensive, core knowledge related to the entire discipline of glioblastoma chemoresistance, from its many etiological mechanisms, to specific strategies to reverse resistance Presents current information from an international team of experts on the basic science, pre-clinical research, and clinical management of glioblastoma chemoresistance Discusses molecular and cellular mechanisms behind therapy resistant glioblastoma cells, as well as the therapeutic strategies available to counter this resistance

Systemic Drug Delivery Strategies: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Volume 2 examines the challenges of delivering immuno-oncology therapies, focusing specifically on the multiple technologies of affective drug delivery strategies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. This volume of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy discusses methods of targeting tumors, CRISPR technology, and vaccine delivery among many other delivery strategies. Systemic Drug Delivery Strategies: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Volume 2 creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. Comprehensive treaty covering all aspects of immuno-oncology (IO) Novel strategies for delivery of IO therapeutics and vaccines Forecasting on the future of nanotechnology and drug delivery for IO

Brain tumors comprise a spectrum of histological patterns. Their presentation and management depend on their location, size, and grade of lesions. This book is a collection of high-quality research work from global experts on brain tumors, including meningiomas, and their treatment.

In the last few years, the development of new technologies in the medical field has allowed procedures and improved surgical techniques to be performed, which until recently would have been unthinkable.Modern neurosurgery is forever tied to technological progress: the development of robotics and robotic-assisted surgery; enhanced visualization, perfusion, and function monitoring in vascular surgery; new techniques of bone reconstruction; new cerebral imaging tools; and alternative treatments such as laser interstitial thermal therapy or immunotherapy for tumors. This book is designed to be a comprehensive introduction to these new developments and to their application in clinical practice. We have tried to provide a unique background and insights to coherently present these new technologies.